Diffuse Large B Cell Lymphoma: Updates on Diagnosis, Treatments and Technologies - Volume II

Diffuse Large B Cell Lymphoma (DLBCL) is the most common Non-Hodgkin Lymphoma in Western countries and is comprised of a heterogeneous group of biologically distinct entities resulting in the clonal proliferation of a germinal or post-germinal malignant B cell. The disease is particularly aggressive with 40% of the afflicted individuals succumbing to the disease.

The standard treatment for DLBCL is still chemo-immunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Whilst this modality is safe and effective, up to 45%–50% of patients will relapse. Despite advances in therapy, DLBCL remains a challenging disease to manage, with significant heterogeneity in clinical presentation and outcomes. Therefore, there is a need to update the medical community with the latest updates in the diagnosis and treatment of DLBCL.

As the Volume II of our 2023 collection, this Research Topic aims to highlight advances in DLBCL management, spanning diagnosis, prognostic factors, therapeutic strategies, and innovative technologies. We welcome submissions on, but not limited to:

- The role of immunotherapy and cellular therapies in the management of DLBCL

- New and emerging treatment options and improving the prognostic outlook for patients.

- Updates and discoveries surrounding new subtypes of DLBCL and co-morbidity of DLBCL with other debilitating factors and diseases.

- Novel predictive biomarkers, prognostic factors, and risk stratification

- Updates on the genetic and molecular landscape of DLBCL

- Management of relapsed/refractory disease

-Advances in diagnostic technologies, including molecular profiling and next-generation sequencing

-Integration of digital pathology and AI-driven tools to improve classification, prognosis, and treatment selection


Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Systematic Review
• Technology and Code

Keywords: DLBCL, diagnosis, treatment, lymphoma, hematologic malignancies

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.